#United States #San Diego #Healthcare Conference #Investor Relations #Neurocrine Biosciences

Neurocrine Biosciences to Present at Upcoming Investor Conferences

Neurocrine Biosciences, Inc. (Nasdaq: NBIX), renowned for its commitment to advancing neurological science, is gearing up for a significant presence at four prominent investor conferences this September. This initiative marks an important opportunity for the company to showcase its portfolio and connect with key stakeholders in the healthcare investment community.

Conference Schedule

The company's executives are set to speak at various high-profile events, aiming to provide valuable insights into their operational direction and advancements in biopharmaceuticals. Here’s the lineup:

• - Cantor Global Healthcare Conference 2025

Presenters include CFO Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla. The presentation is scheduled for 1:00 PM ET on Wednesday, September 3, 2025.

• - Morgan Stanley 23rd Annual Global Healthcare Conference

The spotlight will be on CEO Kyle Gano and Chief Medical Officer Sanjay Keswani at 10:45 AM ET on Tuesday, September 9, 2025.

• - Baird 2025 Global Healthcare Conference

This session will feature CEO Kyle Gano, CMO Sanjay Keswani, and VP of Investor Relations Todd Tushla at 10:15 AM ET on Wednesday, September 10, 2025.

• - TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Virtual Summit

Closing the month, CEO Kyle Gano and VP Todd Tushla will present at this virtual summit at 12:40 PM ET on Wednesday, September 17, 2025.

Live Webcasts and Replays

Each presentation will be accessible via live webcasts on the Neurocrine Biosciences website, specifically in the Investors section. For those unable to attend live, replays will be available approximately one hour post-event and can be accessed for up to a month thereafter. This feature ensures that all interested parties have the opportunity to glean insights from these essential presentations.

About Neurocrine Biosciences

Neurocrine Biosciences stands at the forefront of neuroscience-focused biopharmaceutical innovation, driven by a singular purpose: to alleviate suffering for patients with significant medical needs. With a strong dedication to discovering and developing transformative treatments, Neurocrine focuses on addressing underrecognized neurological, neuroendocrine, and neuropsychiatric disorders.

Their extensive portfolio includes various FDA-approved therapies aimed at complex conditions such as tardive dyskinesia, Huntington's disease-associated chorea, and others. Additionally, Neurocrine is advancing multiple compounds in mid- to late-phase clinical developments, reinforcing its commitment to enhancing patient care in these vital areas.

With over three decades of harnessing deep insights into brain and body interconnections, the company relentlessly pursues innovative medicines that alleviate the burdens of debilitating diseases. They champion the ethos of 'Brave Science,' highlighting their audacious commitment to turning scientific possibilities into real-world solutions for patients.

To explore more about their innovations and updates, visit neurocrine.com and engage with them on platforms like LinkedIn, X, and Facebook.

In conclusion, Neurocrine Biosciences' active participation in this month's investor conferences reflects their strategic focus on transparency and engagement with the investment community, reinforcing their position as a leader in biopharmaceutical advancements.

Stay tuned for further updates as the company continues on its mission to revolutionize healthcare.